Merck (MRK) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
12 Nov, 2026Executive summary
Q3 net sales rose 5.8% YoY to €5.627bn, with 5.1% organic growth; EBITDA pre increased 0.8% to €1.682bn. Growth was led by Life Science and Electronics.
FY 2026 guidance was raised for net sales, EBITDA pre and free cash flow, while reported earnings were pressured by a €366m CDMO impairment.
Financial highlights
Q3 reported sales growth comprised 5.1% organic growth, a 1.5-point FX contribution and a 0.8-point negative portfolio effect.
EBITDA pre was €1.682bn versus €1.669bn, up 0.8% reported and 0.4% organically; EPS pre was €2.32, unchanged YoY.
EBIT fell to €653m from €1.221bn; profit after tax was €450m versus €898m, and reported EPS was €1.04 versus €2.07.
Operating cash flow rose 9.4% to €1.660bn and free cash flow increased 22.7% to €1.317bn.
9M sales rose 2.2% to €16.195bn; EBITDA pre increased 3.1% to €4.811bn and EPS pre rose 2.0% to €6.59.
Outlook and guidance
FY 2026 net sales guidance: €21.5bn–€21.9bn, with organic growth of 3%–4% and FX impact of -1% to 0%; EBITDA pre guidance: €6.2bn–€6.4bn, with organic growth of 3%–5%.
EPS pre guidance is €8.30–€8.70; free cash flow guidance increased to €2.3bn–€2.7bn.
Guidance assumes Bio-Techne contributes in December 2026 and no U.S. Mavenclad sales from November; EBITDA pre FX impact is forecast at -2% to 0%.
Segment sales guidance: Life Science €9.4bn–€9.6bn, Healthcare €8.5bn–€8.7bn and Electronics ~€3.6bn; Electronics organic growth guidance is 10%–11%.
FY 2026 capex on PPE is guided at €1.3bn–€1.5bn; the underlying tax rate is expected at 22%–24% from 2027.
Latest events from Merck
- A €0.9bn proposal adds a promising siRNA asset for rare blood cancer.MRK
Acquisition presentation - AI-linked semiconductor demand and Rare Diseases growth supported Q3 as FY26 guidance rose.MRK
Q3 2026 (Media) - Growth fueled by innovation, strategic M&A, and sustainability across all business sectors.MRK
Corporate presentation - Upgraded 2026 guidance as Life Science and Electronics drive growth, with margin expansion.MRK
Q2 2026 - Strong early oncology pipeline progress with promising DDR and ADC assets advancing to clinic.MRK
Investor Update - Q3 2025 delivered robust organic growth, higher margins, and a positive outlook despite FX risks.MRK
Q3 2025 - Growth and margin expansion driven by rare diseases, semiconductor solutions, and innovation.MRK
CMD 2025 - Growth, innovation, and sustainability drive upgraded ambitions and operational excellence.MRK
CMD 2024 - Q1 2025 delivered solid growth and margin gains, with guidance reflecting macro headwinds.MRK
Q1 2025